S.C. Radiologia Ospedale Maggiore, Piazza Ospitale 1, 34134 Tieste, Italy.
Eur Radiol. 2011 Dec;21(12):2527-41. doi: 10.1007/s00330-011-2225-0. Epub 2011 Aug 25.
The Contrast Media Safety Committee (CMSC) of the European Society of Urogenital Radiology (ESUR) has updated its 1999 guidelines on contrast medium-induced nephropathy (CIN).
Topics reviewed include the definition of CIN, the choice of contrast medium, the prophylactic measures used to reduce the incidence of CIN, and the management of patients receiving metformin. Key Points • Definition, risk factors and prevention of contrast medium induced nephropathy are reviewed. • CIN risk is lower with intravenous than intra-arterial iodinated contrast medium. • eGFR of 45 ml/min/1.73 m (2) is CIN risk threshold for intravenous contrast medium. • Hydration with either saline or sodium bicarbonate reduces CIN incidence. • Patients with eGFR ≥ 60 ml/min/1.73 m (2) receiving contrast medium can continue metformin normally.
欧洲泌尿生殖放射学会（ESUR）对比剂安全委员会（CMSC）更新了其 1999 年关于对比剂肾病（CIN）的指南。
审查的主题包括 CIN 的定义、对比剂的选择、降低 CIN 发生率的预防措施以及接受二甲双胍治疗的患者的管理。
回顾了对比剂诱导肾病的定义、危险因素和预防。
与动脉内碘对比剂相比，静脉内碘对比剂的 CIN 风险较低。
静脉对比剂的 CIN 风险阈值为 eGFR45ml/min/1.73m²。
生理盐水或碳酸氢钠水化可降低 CIN 的发生率。
接受对比剂治疗且 eGFR≥60ml/min/1.73m²的患者可以继续正常使用二甲双胍。
